ZITUVIMET

Growth

sitagliptin and metformin hydrochloride

NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
30/100

Mechanism of Action

Dipeptidyl Peptidase 4 Inhibitors

Pharmacologic Class:

Dipeptidyl Peptidase 4 Inhibitor

External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers